186 related articles for article (PubMed ID: 34484797)
1. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Ota T; Okabayashi A; Fukuoka M
Respirol Case Rep; 2021 Oct; 9(10):e0841. PubMed ID: 34484797
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
3. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
4. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
Xue Y; Ren Y; Yan B; Li Z; Huang C
Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
6. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in
Hirai N; Hatanaka Y; Hatanaka KC; Uno Y; Chiba SI; Umekage Y; Minami Y; Okumura S; Ohsaki Y; Sasaki T
Transl Lung Cancer Res; 2021 Sep; 10(9):3737-3744. PubMed ID: 34733624
[TBL] [Abstract][Full Text] [Related]
8. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
Moschetta M; Mak G; Hauser J; Davies C; Uccello M; Arkenau HT
Exp Hematol Oncol; 2017; 6():1. PubMed ID: 28078189
[TBL] [Abstract][Full Text] [Related]
9. EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF
Zeng R; Luo L; Sun X; Bao Z; Du W; Dai R; Tang W; Gao B; Xiang Y
Cancer Drug Resist; 2021; 4(4):1019-1027. PubMed ID: 35582379
[TBL] [Abstract][Full Text] [Related]
10.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
12. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance in a
Schmid T; Buess M
Curr Oncol; 2018 Jun; 25(3):e217-e219. PubMed ID: 29962848
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
Sánchez-Torres JM; Viteri S; Molina MA; Rosell R
Transl Lung Cancer Res; 2013 Jun; 2(3):244-50. PubMed ID: 25806238
[TBL] [Abstract][Full Text] [Related]
17. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.
Ernst T; Aebi S; Zander A; Zander T
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35396243
[TBL] [Abstract][Full Text] [Related]
18. Trametinib: a MEK inhibitor for management of metastatic melanoma.
Lugowska I; Koseła-Paterczyk H; Kozak K; Rutkowski P
Onco Targets Ther; 2015; 8():2251-9. PubMed ID: 26347206
[TBL] [Abstract][Full Text] [Related]
19. Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.
Maniar R; Gallitano SM; Husain S; Moazami G; Weiss MJ; Shu CA
J Natl Compr Canc Netw; 2023 Feb; 21(3):232-234. PubMed ID: 36758579
[TBL] [Abstract][Full Text] [Related]
20. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
Dimou A; Barron G; Merrick DT; Kolfenbach J; Doebele RC
BMC Cancer; 2020 Mar; 20(1):177. PubMed ID: 32131760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]